Clinical features of MTX-related pancytopenia

Clinical features of MTX-related pancytopenia - Clinical features of MTX-related pancytopenia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020906

Enrollment

Registered

2016-02-07

Start date

2014-09-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthhritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cytopenia patients induced by low dose MTX therapy. And age and sex matched control.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
eGFR eGFR corrected by body surface area Duration from MTX administration MTX dose at onset of pancytopenia Presence of acute renal insuffciency Preceded dehyration	—

Countries

Japan

Contacts

Public ContactKokubo Katsunori

NHO Kumamoto Saishunsou National Hospital Rheumatology

8211syo1@hosp.go.jp81-96-242-1000

Outcome results